By CE2023-02-08T14:57:35
GlobalData says CD19 CAR-T agents are expected to treat over 13,000 blood cancer patients annually by 2031, driving sales of Breyanzi and Yescarta.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2027-01-27T15:00:00Z
Sponsored by Cell Signaling Technology
2026-11-19T09:05:00Z
Sponsored by PCI Pharma Services
2026-11-18T09:06:00Z
Sponsored by Quotient Sciences, By Dr Asma Patel and Robert Cornog
2026-11-19T09:05:00
Sponsored by PCI Pharma Services
2026-10-14T14:00:00
Sponsored by Particle Measuring Systems
2026-06-15T07:55:00
Sponsored by Octave, By Adam Cross
2026-06-29T06:00:00
Sponsored by Lubrizol Advanced Materials Europe BV
2026-03-18T15:00:00
Sponsored by Sartorius
Site powered by Webvision Cloud